Argenx

This phase 3 trial tests whether empasiprubart, given by IV infusion, can help adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and disability. The study will enroll 160 participants. For the first 6 months, some get the …

This study is testing two drugs, efgartigimod and empasiprubart, given by IV, to see if they are safe and work well for people with myasthenia gravis (MG). The goal is to reduce side effects and improve quality of life. About 70 adults with MG are being recruited.

This study tests whether adding empasiprubart to the existing drug efgartigimod can improve symptoms and daily function in people with generalized myasthenia gravis who still have symptoms on efgartigimod alone. About 70 participants will receive both drugs intravenously. The mai…

This study tests a new medicine called empasiprubart against the standard treatment (IVIg) for people with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease that causes weakness and numbness. About 218 adults who have used IVIg before will receive either t…

This study tests an IV drug called efgartigimod in teens aged 12 to 18 with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bruising and bleeding. The goal is to find the right dose and see if it safely raises platelet counts…

This study tests a drug called efgartigimod in 12 children aged 2 to 18 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to find the right dose and see if it is safe. Participants receive injections and are monitored for up to 14 weeks.

This study tests a new biologic drug called ARGX-119 in children aged 5 to 17 with spinal muscular atrophy (SMA). About 60 participants will receive either ARGX-119 or a placebo by IV infusion for 24 weeks, alongside their usual SMA therapy. The goal is to find the best dose and …

This study follows 100 adults in Italy with generalized myasthenia gravis who are starting efgartigimod as part of their routine care. Researchers will track changes in symptoms and daily activities over up to 23 months using patient reports and doctor assessments. The goal is to…

This study tests an investigational IV drug called efgartigimod in adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. About 69 participants will receive either the drug or a placebo for up to 24 weeks,…

This early-stage trial tests a new biologic drug called ARGX-119 in 16 adults with a rare genetic muscle weakness condition called DOK7-congenital myasthenic syndrome (CMS). The study aims to see if the drug is safe and how the body processes it. Participants will receive either …

This study follows 200 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are starting treatment with efgartigimod. Researchers will track changes in disability, grip strength, and quality of life over up to 2 years in everyday clinical settings. The…

This study tests an experimental drug called efgartigimod PH20 SC in adults with systemic sclerosis, a disease that causes skin thickening and organ problems. About 81 participants will receive either the drug or a placebo as a shot under the skin for up to 48 weeks. Researchers …

This program offers efgartigimod PH20 SC to adults with CIDP who cannot join clinical trials and have not been helped by existing treatments. The drug is injected under the skin and aims to control the disease. The program continues until the patient stops treatment or the drug b…

This study tests a drug called efgartigimod, given as a shot under the skin, for people who have antibody-mediated rejection after a kidney transplant. The trial includes 30 adults who received a kidney at least 6 months ago and have signs of rejection. Participants will receive …

This study tests a drug called efgartigimod in 30 adults who were diagnosed with generalized myasthenia gravis (gMG) within the past year. The goal is to see if it can quickly reduce muscle weakness and daily-life symptoms. Participants receive weekly injections for about a year,…

This study is testing a drug called efgartigimod in children aged 2 to 17 with generalized myasthenia gravis, a condition that causes muscle weakness. The drug is given through an IV and aims to lower harmful antibodies. Researchers will check how the drug moves through the body,…

This study tests a drug called adimanebart in healthy adults to see how much of it gets into the bloodstream and how body weight affects that process. Participants receive a single dose either by IV or as an injection under the skin. Researchers will measure drug levels over time…

This study is for people with a rare genetic muscle condition called congenital myasthenic syndrome (CMS). It does not test any new drug or treatment. Instead, researchers will collect information from up to 100 participants over 4 visits to better understand how the disease affe…

This study looks at how the body absorbs a drug called empasiprubart when given as a shot under the skin using an autoinjector compared to through an IV. It involves 130 healthy adults aged 18 to 65. The goal is to understand the drug's behavior and safety, not to treat any disea…

This early-stage study tests whether ARGX-124 is safe in healthy adults aged 18 to 65. Researchers will also measure how the drug moves through the body and how the immune system reacts. About 104 participants will receive either the drug or a placebo, and the study lasts up to 2…

This study follows pregnant women who have taken efgartigimod for myasthenia gravis or CIDP, as well as women exposed only during breastfeeding. Researchers will monitor pregnancy outcomes and infant health, including birth defects, to better understand the drug's safety. The goa…

This study follows 680 people with generalized myasthenia gravis to see how safe efgartigimod is over the long term. Some participants take the drug, while others do not. Researchers will compare rates of serious infections and other side effects between the two groups.